Abstract
Serum biomarker studies on patients with severe COVID-19 lung disease indicate that increased ligands for Receptor for Advanced Glycation End-products (RAGE) and diabetes are risk factors for severe acute respiratory distress syndrome (ARDS).
Highlights
Older patients with obesity and/or chronic diseases such as hypertension, underlying chronic lung disease, and diabetes are at highest risk for developing severe complications of COVID-19 lung disease and dying from acute respiratory distress syndrome (ARDS) [1,2,3]
These findings in a small group of carefully selected decedents who died from COVID-19 ARDS suggest that Receptor for Advanced Glycation End-products (RAGE) expression is significantly increased in a setting of COVID-19 and diabetes and likely plays a role in fatal outcome
To further investigate the role of RAGE expression in COVID-19 lung disease, we evaluated lung tissues from patients with Severe Acute Respiratory Syndrome (SARS)-CoV-2 confirmed by polymerase chain reaction (PCR) who died with ARDS during the height of the pandemic in NYC in spring 2020
Summary
Older patients with obesity and/or chronic diseases such as hypertension, underlying chronic lung disease, and diabetes are at highest risk for developing severe complications of COVID-19 lung disease and dying from acute respiratory distress syndrome (ARDS) [1,2,3]. RAGE ligands S100 and high mobility group box 1 (HMGB1) mediate pathogen-associated molecular patterns (PAMPS) and Damage Associated Molecular Patterns (DAMPS) that perpetuate and amplify inflammatory responses in the lung to infectious agents [5,6,7,8]. These serum biomarkers have been associated with increased mortality in COVID-19 patients [9,10]. Serum biomarker studies on patients with severe COVID-19 lung disease indicate that increased ligands for Receptor for Advanced Glycation End-products (RAGE) and diabetes are risk factors for severe acute respiratory distress syndrome (ARDS)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Pathology and Clinical Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
